Cargando…

Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity

BACKGROUND: Discordance between patient and physician ratings of rheumatoid arthritis (RA) severity occurs in clinical practice and correlates with pain scores and measurements of joint disease. However, information is lacking on whether discordance impacts patients’ ability to work. We evaluated th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smolen, Josef S., Strand, Vibeke, Koenig, Andrew S., Szumski, Annette, Kotak, Sameer, Jones, Thomas V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4875609/ https://www.ncbi.nlm.nih.gov/pubmed/27209012 http://dx.doi.org/10.1186/s13075-016-1004-3

Ejemplares similares

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial
por: Smolen, Josef S., et al.
Publicado: (2018)

Discordant patient–physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis
por: Karpouzas, George A, et al.
Publicado: (2017)

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2019)

Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity
por: Karpouzas, George A, et al.
Publicado: (2018)

Impact of etanercept tapering on work productivity in patients with early rheumatoid arthritis: results from the PRIZE study
por: Zhang, Wei, et al.
Publicado: (2016)

Discordance between the patient’s and physician’s global assessment in rheumatoid arthritis: Data from the REAL study—Brazil
por: Guimarães, Maria Fernanda Brandão Resende, et al.
Publicado: (2020)

Discordance of global assessment between the patients and physicians predicts 9-year pain-related outcomes in rheumatoid arthritis patients
por: Hayashi, Kazuhiro, et al.
Publicado: (2023)

The science of rheumatoid arthritis: a prelude
por: Smolen, Josef S
Publicado: (2005)

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment
por: Strand, Vibeke, et al.
Publicado: (2012)

Autoantibodies in rheumatoid arthritis and their clinical significance
por: Steiner, Günter, et al.
Publicado: (2002)

Developments in the clinical understanding of rheumatoid arthritis
por: Smolen, Josef S, et al.
Publicado: (2009)

Randomized controlled trial design in rheumatoid arthritis: the past decade
por: Strand, Vibeke, et al.
Publicado: (2009)

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
por: Smolen, Josef S., et al.
Publicado: (2015)

Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor
por: Tan, Eng M., et al.
Publicado: (2016)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol
por: Hazes, Johanna M., et al.
Publicado: (2010)

Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis
por: Reed, George W., et al.
Publicado: (2017)

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
por: Michaud, Kaleb, et al.
Publicado: (2019)

Increased DNA methylation variability in rheumatoid arthritis-discordant monozygotic twins
por: Webster, Amy P., et al.
Publicado: (2018)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
por: Strand, Vibeke, et al.
Publicado: (2011)

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses
por: Strand, Vibeke, et al.
Publicado: (2018)

Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
por: Aletaha, Daniel, et al.
Publicado: (2015)

Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation
por: Challa, Divya N., et al.
Publicado: (2017)

Estimating the monetary value of the annual productivity gained in patients with early rheumatoid arthritis receiving etanercept plus methotrexate: interim results from the PRIZE study
por: Zhang, Wei, et al.
Publicado: (2015)

Impact of Rheumatoid Arthritis Disease Activity Test on Clinical Practice
por: Peabody, John W., et al.
Publicado: (2013)

Factors Contributing to Discordance between the 2011 ACR/EULAR Criteria and Physician Clinical Judgment for the Identification of Remission in Patients with Rheumatoid Arthritis
por: Sung, Yoon-Kyoung, et al.
Publicado: (2016)

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib
por: Strand, Vibeke, et al.
Publicado: (2020)

Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis
por: Strand, Vibeke, et al.
Publicado: (2018)

Response to ‘Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis’
por: Vastesaeger, Nathan, et al.
Publicado: (2015)

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
por: Fleischmann, Roy M, et al.
Publicado: (2017)

Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs
por: Radner, Helga, et al.
Publicado: (2014)

Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
por: Dikranian, Ara, et al.
Publicado: (2021)

Discrepancy between patient and physician in assessment of global severity in early rheumatoid arthritis
por: Kaneko, Yuko, et al.
Publicado: (2012)

Physician global assessments for disease activity in rheumatoid arthritis are all over the map!
por: Turk, Matthew, et al.
Publicado: (2018)

Productivity at work and quality of life in patients with rheumatoid arthritis
por: van Vilsteren, Myrthe, et al.
Publicado: (2015)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients
por: Radner, Helga, et al.
Publicado: (2015)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Value of self-performed joint counts in rheumatoid arthritis patients near remission
por: Radner, Helga, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nfvl8ko6c2p8654a6g4qqroe62